Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy
- 1.6k Downloads
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects millions of patients worldwide. The current disease-modifying therapies (DMTs) that are widely used to treat MS only show modest effects. Because MS is a chronic disease, it is important to develop treatments that have better long-term efficacy. Recently, several new-generation DMTs have been developed, most of which target specific immune molecules based on the assumption that MS is an autoimmune disease. These DMTs are designed to inhibit inflammation that is thought to directly cause demyelination. Preliminary studies suggest that these new therapies are likely to show a greater effect in reducing relapses in early MS patients, although their long-term efficacy is still unknown. In contrast, it was recently reported that the initial course of MS does not significantly influence long-term disability and that disability increases approximately at the same rate despite variable relapse frequencies. Furthermore, new neuropathological evidence now argues against the autoimmune hypothesis and suggests that MS is a primary oligodendrogliopathy disease in which the inflammatory response may be a mere epiphenomenon. So can we be optimistic about the unproven long-term outcomes of new DMTs or should we reconsider the pathogenesis of MS when developing more disease-specific treatments?
KeywordsMultiple sclerosis Pathogenesis Autoimmune Oligodendrogliopathy
Jin Nakahara is supported by the Keio University KANRINMARU Project. This work was supported by research grant #09-24 from the National Institute of Biomedical Innovation of Japan, by Special Coordination Funds for Promoting Science and Technology from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), and by Grants-in-Aid for Scientific Research from MEXT.
- 1.The IFNβ Multiple Sclerosis Study Group (1993) Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661Google Scholar
- 3.The Copolymer 1 Multiple Sclerosis Study Group (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268–1276Google Scholar
- 25.The Lenercept Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457–465Google Scholar
- 27.Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor a antagonism: by what mechanisms could tumor necrosis factor a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44:1977–1983PubMedCrossRefGoogle Scholar
- 28.Segal BM, Constantinescu CS, Raychaudhuri A et al (2008) Repeated subcutaneous injections of IL12/23 p40 neutralizing antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol 7:796–804PubMedCrossRefGoogle Scholar
- 33.Nielsen HH, Toft-Hansen H, Lambertsen KL, Owens T, Finsen B (2011) Stimulation of adult oligodendrogenesis by myelin-specific T cells. Am J Pathol, doi: 10.1016/j.ajpath.2011.06.006
- 36.Charcot J (1868) Histologie de la sclérose en plaque. Gazette des Hôpitaux 41:554–566Google Scholar
- 60.Howell OW, Reeves CA, Nicholas R et al (2011) Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. doi: 10.1093/brain/awr182, advance access